The amelioration of hepatic steatosis and normalization of liver enzymes, hepatic inflammatory markers (IL-6, TNF-α, IL-1β, CRP, MCP-1, COX2), endogenous antioxidant system molecules, and regulated enzymes involved in lipid and glucose metabolism in vivo using a high-fat-diet-induced murine obesity model also implied the hepatoprotective potential of withaferin A [134,136,137]. Here, CCL2 is linked to obesity disorder.